Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Abemaciclib,ABC1234,2022,USA,MDV,350,62,98,2,27.5,15,92,5,10,45,30,15,55,30,10,5,15,40,35,12,3,2,5,4,25,60,50,AC,Taxol,CMF,Taxol,30,35,35,40,25,30,20,50,30,60,2
Abemaciclib,DEF5678,2023,UK,Claim Database,420,68,97,3,28.1,18,88,7,12,40,33,15,50,35,10,5,18,35,37,15,4,3,6,5,28,65,55,EC,Docetaxel,FEC,Docetaxel,32,33,35,45,30,35,15,55,30,70,3
Abemaciclib,GHI9012,2023,Canada,MDV,280,65,99,1,29.0,12,90,6,8,48,32,12,60,28,8,4,12,42,36,10,2,1,4,3,22,58,48,AC,Cyclophosphamide,CMF,Doxorubicin,28,37,35,38,22,28,25,45,30,55,2.5
Abemaciclib,JKL3456,2024,Australia,Claim Database,480,70,96,4,30.2,20,85,8,15,38,35,12,48,37,11,4,20,33,37,18,5,4,7,6,30,70,60,FEC,Carboplatin,Taxol,AC,35,32,33,50,35,40,10,60,30,75,3.5
